Skip to content
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Axim Biotechnologies, Inc. AXIM

13 fiscal years on record · USD · FY2023 reported · SEC filings only
$39,518
▲ 345.3% YoY
$-8.1M
$-1.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 39,518.00
Revenue, FY2023 · full 13-year series below
Revenue $M Net income $M
FY2023 · Revenue 0.0 · Net income -8.1
-10M-20M
20112014201720202023
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2023 · Operating -6961.0% · Net ·
-20000%-40000%
201120172023
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2023 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -1.0
-2M-3M
201120172023

Total assetsUSD 4.1M
EquityUSD -7.7M
CashUSD 156,457.00
Gross debtUSD 0.00
Net debtUSD -156,457.00
Current ratio0.03×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 13-year record

13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
AXIM, 13-year financial record
Metric 2023202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
Income tax $B0.00.00.00.00.00.00.00.00.00.0◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0◌◌◌−0.0−0.0−0.0◌◌◌
EPS, diluted $−0.04−0.040.12−0.06−0.10−0.12−0.08−0.17−0.27−0.020.00◌0.00
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————
ROE %————————————−27.4
Shares out B0.250.190.140.130.060.060.050.050.040.030.030.030.03

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 52 reconciliationsAUDITED

Reconciled in 13 of the 13 fiscal years we could check. Eight checks were skipped: the balance sheet is not tagged before 2011. Seven checks were skipped: cost of revenue is not tagged before 2014. Four checks were skipped: EPS is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image